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Summary. Background: Peroxisome proliferator-activated
receptor-c (PPARc) is expressed in human platelets although
in the absence of genomic regulation in these cells, its functions
are unclear. Objective: In the present study, we aimed to
demonstrate the ability of PPARc ligands tomodulate collagen-
stimulated platelet function and suppress activation of the
glycoprotein VI (GPVI) signaling pathway.Methods:Washed
platelets were stimulated with PPARc ligands in the presence
and absence of PPARc antagonist GW9662 and collagen-
induced aggregation wasmeasured using optical aggregometry.
Calcium levels were measured by spectroﬂuorimetry in Fura-
2AM-loaded platelets and tyrosine phosphorylation levels of
receptor-proximal components of the GPVI signaling pathway
were measured using immunoblot analysis. The role of PPARc
agonists in thrombus formation was assessed using an in vitro
model of thrombus formation under arterial ﬂow conditions.
Results: PPARc ligands inhibited collagen-stimulated platelet
aggregation that was accompanied by a reduction in intracel-
lular calcium mobilization and P-selectin exposure. PPARc
ligands inhibited thrombus formation under arterial ﬂow
conditions. The incorporation of GW9662 reversed the inhib-
itory actions of PPARc agonists, implicating PPARc in the
eﬀects observed. Furthermore, PPARc ligands were found to
inhibit tyrosine phosphorylation levels of multiple components
of the GPVI signaling pathway. PPARcwas found to associate
withSykandLATafter platelet activation.This associationwas
prevented by PPARc agonists, indicating a potential mecha-
nism for PPARc function in collagen-stimulated platelet
activation. Conclusions: PPARc agonists inhibit the activation
of collagen-stimulation of platelet function throughmodulation
of early GPVI signalling.
Keywords: glycoproteinVI,nuclearreceptor,platelets,signaling.
Introduction
Diabetes mellitus is a major risk factor for vascular diseases
and is associated with atherosclerosis and thrombotic compli-
cations [1]. Platelets play an important role in hemostasis and
thrombosis, and are becoming increasingly implicated in
inﬂammation and host defense mechanisms contributing to
the pathogenesis and progression of the vascular complications
of diabetes mellitus [2,3]. When blood vessels become damaged
this results in the local exposure, generation or release of factors
such as collagen and thrombin that trigger the function of
platelets, initiating the hemostatic process. Platelet activation is
associated with signaling that results in shape change and
spreading, secretion and the release of multiple prothrombotic
factors, and through the binding of plasma ﬁbrinogen and von
Willebrand factor (VWF) to integrin aIIbb3, this leads to the
formation of a stable platelet thrombus [2,4,5].
Collagen binding to the platelet receptor glycoprotein VI
(GPVI) results in clustering thereby triggering the tyrosine
phosphorylation of the associated transmembrane protein, the
Fc receptor c-chain by the Src-family kinasesLyn andFyn [6,7].
This results in the binding of the tyrosine kinase Syk, which
becomes tyrosine phosphorylated and activated, leading to the
tyrosinephosphorylationofthetransmembraneadaptorprotein
linker for activationofT-cells (LAT).LAT forms aplatform for
the assemblyof a signaling complex that includes phospholipase
Cc2 (PLCc2) which in turn becomes tyrosine phosphorylated.
Phosphoinositide 3-kinase (PI3-K) is also recruited and through
the generation of phosphatidylinositol (3, 4, 5)-trisphosphate,
inﬂuences the recruitment and activation of phospholipase Cc2
(PLCc2), which liberates the second messengers 1,2-diacylglyc-
erol and inositol 1,4,5-trisphosphate. The formation of these
molecules is responsible for the mobilization of calcium from
intracellularstoresandactivationof isoformsofproteinkinaseC
(PKC) leading to secretion and aggregation. PI3-K activity
results in the regulation of protein kinase B (PKB), which is
important for platelet function and thrombus formation [2,8,9].
The peroxisome proliferator-activated receptors (PPARs)
consist of a family of three nuclear receptor isoforms (a, b/d,
and c) that heterodimerize with the retinoic X receptor (RXR)
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and then modulate transcription of target genes [10]. PPARs
play important roles in the regulation of metabolic pathways,
including lipid biosynthesis and glucose metabolism [10,11].
This and implicated roles in cell differentiation, proliferation
and inﬂammation have led to the hypothesis that the actions of
PPARs may be associated with the prevention of cardiovas-
cular complications [10–12]. Although platelets lack a nucleus,
we and others have reported that they express a number of
transcription factors including the steroid/nuclear receptors
such as PPARc, PPARb/d, the glucocorticoid receptor (GR),
oestrogen receptor (ER), retinoic X receptor (RXR) and NF-
jB [13–19]. While steroid/nuclear receptors are recognized for
their role in gene regulation, increasing evidence supports non-
genomic actions of these receptors [20,21]. These studies have
demonstrated that steroid hormones can induce rapid non-
genomic modulation of cell function, although mechanisms
have not been established for the non-genomic actions of the
majority of these receptors.
The synthetic and clinically used drug rosiglitazone and the
endogenous prostaglandin 15-deoxy-D12,14-prostaglandin J2
(15d-PGJ2) are ligands of PPARc [10]. Rosiglitazone is a
memberofthethiazolidinedione(TZD)familyusedtotreattype
2 diabetes mellitus that effectively lowers blood glucose levels
althoughimprovingsensitivitytoinsulin [22,23].Severalclinical
studies have demonstrated that the treatment of diabetic
patientswiththiazolidinedionesexertsacardioprotectiveeffect,
indicated by a reduction in the risk of myocardial infarction in
diabetic patients with an acute coronary syndrome [24–26].
In the present study, we investigated the effects of PPARc
agonists, 15d-PGJ2 and rosiglitazone on collagen-stimulated
platelet activation, signaling and on thrombus formation. We
demonstrate that PPARc ligands modulate the activity of the
GPVI collagen receptor-stimulated signaling pathway resulting
in reduced levels of platelet activation, aggregation and
thrombus formation under arterial ﬂow conditions.
Materials and methods
Reagents
15d-PGJ2, SQ29548 and GW-9662 were purchased from
Biomol (Afﬁnity Research Products, Exeter, UK). Rosiglitaz-
one was from Cayman Chemical (Alexis Corporation, Not-
tingham, UK). Horm-Chemie collagen was from Nycomed
(Munich, Germany) and collagen-related peptide (CRP) from
Professor Richard Farndale (University of Cambridge, UK).
Anti-Syk (N-19, LR), anti-PPARc (E8), anti-LAT, anti-PLCc2
antibodies and protein A/G agarose were purchased from
Santa Cruz Biotechnology (Autogen Bioclear UK). Anti-Akt/
PKBa was purchased from Upstate Biotechnology (Dundee,
Scotland). PE-Cy5 labeled anti-CD62P(P-selectin) was ob-
tained from BD Biosciences (Oxford, UK) and MRS2179,
Fura-2 AM and dimethylsulfoxide (DMSO) were from Sigma
(Poole, UK). All other reagents were from previously described
sources [27,28]. PECAM-1 knockout mice were provided by
Professor T. Mak (University of Toronto, ON, Canada). All
protocols involving the use of animals were approved by
University of Reading Ethical Review Panel and authorized by
a Home Ofﬁce licence.
Human platelet aggregation assay
Washed platelets were prepared from fresh blood obtained
from aspirin-free donors by differential centrifugation and
aggregation measured by optical aggregometry (Chrono-log
Corp., Havertown, PA, USA) as described previously [29].
Informed consent from human subjects was obtained and
procedures approved by the University of Reading Research
Ethics Committee.
Mouse platelet aggregation assay
Platelets were isolated from mouse blood (PECAM-1-deﬁcient
mice on a C57/Bl6 genetic background and matched C57/Bl6
controls), by cardiac puncture after termination, washed,
counted using a Z2 coulter counter (Beckman Coulter,
Hialeah, FL, USA) and aggregation assays performed at a
density of 4 · 108 cells mL)1 by optical aggregometry as
described previously [30–32].
Immunoprecipitation and immunoblotting
For protein precipitation assays, platelets were suspended at
8 · 108 cells mL)1 in buffer containing 1 mmol l)1 ethylene
glycol tetraacetic acid (EGTA), 10 lmol L)1 indomethacin
and 2 U mL)1 apyrase to prevent platelet aggregation, release
of TXA2 and the secondary effects of adenosine 5´-diphosphate
(ADP), respectively. Immunoprecipitation, sodium dodecyl-
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting onto polyvinylidine diﬂuoridemembranewere
performed using standard techniques [28,32,33]. Densitometry
wasperformedusingaBio-RadGS-710 calibrateddensitometer
and QUANTITY ONE software (Bio-Rad, Hemel Hempstead,
UK). Data were normalized for protein loading established
through reprobing of each blot for the protein of interest.
Measurement of [Ca2+]i by spectrofluorimetry
Mobilization of calcium from intracellular stores wasmeasured
in platelets pre-loaded with the ﬂuorescent dye FURA-2AM as
described previously [27,33]. Platelets (2 · 108 cell mL)1) were
incubated with PPARc agonist or vehicle [DMSO 0.1% (v/v)]
for 3 min and then stimulated with collagen (1.0 lg mL)1) in a
luminescence spectrophotometer (LS-50B; Perkin Elmer, Bea-
consﬁeld, UK). The ratio of emission values (excitation:340/
380 nm) was calculated and converted to calcium concentra-
tion using FLWINLAB software (Perkin Elmer).
a-granule secretion
To measure a-granule secretion, surface exposure of P-selectin
was assessed in whole blood by ﬂow cytometry as reported
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previously [34]. In these assays the GPVI-selective agonist CRP
was utilized to avoid technical issues encountered with collagen
because of integrin a2b1-dependent adhesion to collagen ﬁbrils.
Thrombus formation in vitro
Whole fresh citrated blood was incubated with the lipophilic
dye 3,3¢-dihexyloxacarbocyanine iodide (DIOC6) and perfused
through collagen-coated (100 lg mL)1) micro-capillaries at a
shear rate of 1000 s)1 in the presence of PPARc agonists 15d-
PGJ2, rosiglitazone or vehicle control. Thrombi were subse-
quently visualized using a Leica DMIRE2 inverted confocal
microscopy (using N PLANL 20·/0.4 objective lens with 0–
2 mm correction) and thrombus volume calculated from Z
series images captured using TCS SP2 software (Leica, UK), as
previously reported [31,32].
Statistical analysis
Aggregation traces are representative of at least three separate
experiments from different donors. Numerical data are
presented as mean ± SEM and statistical signiﬁcance ana-
lyzed using the t-test.
Results
PPARc agonists 15d-PGJ2 and rosiglitazone inhibit
collagen-stimulated platelet aggregation
To determine if the natural PPARc agonist, 15d-PGJ2 and
rosiglitazone modulate platelet activation by the primary
platelet agonist collagen, platelets were incubated with increas-
ing concentrations of 15d-PGJ2, rosiglitazone (1, 3, 10 and
20 lmol L)1) or vehicle [DMSO 0.1% (v/v)] for 3, 15 or
20 min prior to stimulation with collagen (1 lg mL)1) for 90 s.
Platelet aggregation in response to collagen was found to be
inhibited in a concentration-dependent manner by each of the
PPARc agonists 15d-PGJ2 (Fig. 1Ai–ii) and rosiglitazone
(Fig. 1Bi–ii). Aggregation assays performed for up to 5 min
duration conﬁrmed this effect to be inhibition rather than delay
in aggregation (Fig. S1). The extent of inhibition was found to
be dependent of the time of incubation with PPARc agonists,
suggesting that some differences in apparent potencymay be as
a result of the differential ability to cross the plasmamembrane.
Incubation for 15 min with 15d-PGJ2 (Fig. 1Aii) or 20 min
with rosiglitazone (Fig. 1Bii) enabled complete inhibition of
aggregation at a concentration of 10 lmol L)1. The effect of
15d-PGJ2 (3 and 10 lmol L
)1) on platelet aggregation induced
by a range of collagen concentrations (0.1, 0.5, 1, 5, 10 and
25 lg mL)1) was also examined. Levels of inhibition became
reduced signiﬁcantly with increasing concentrations of colla-
gen. Inhibition was, however, maintained at higher concentra-
tions of collagen. Incubation with 15d-PGJ2 (10 lmol L
)1) for
15 min resulted in a signiﬁcant inhibition of platelet aggrega-
tion in response to high concentrations of collagen (10–
25 lg mL)1) (Fig. 1C).
The platelet response to collagen is partially dependent on
the release of secondary agonists, such as ADP and TxA2.
Furthermore, PPARc agonists have been previously reported
to inhibit platelet aggregation induced by ADP [13]. To
examine whether the inhibitory effects of PPARc agonists on
collagen-stimulated aggregation was because of their ability to
inhibit the actions of TxA2 and ADP secreted after stimulation
with collagen, the thromboxane receptor (TPa/TPb) antagonist
SQ29548 and apyrase were used. Figure 2Ai demonstrates the
ability of apyrase to partially inhibit the level of collagen-
(10.0 lg mL)1) stimulated platelet aggregation. At this con-
centration of collagen a maximal level of inhibition was
achieved by 5 U mL)1 apyrase. In the presence of apyrase
(5 U mL)1), the PPARc agonist 15d-PGJ2 increased the
inhibition of platelet aggregation, suggesting that the effects
of PPARc agonists on collagen-stimulated aggregation may
not be explained through inhibition of ADP signaling alone
(Fig. 2Aii–iii). Similar data were obtained using the P2Y1
antagonist MRS2179 (Fig. S2). The TxA2 antagonist SQ29548
partially inhibited collagen-(2.5 lg mL)1) stimulated platelet
aggregation; a maximal level of inhibition was achieved by
10 nmol l)1 SQ29548 (Fig. 2Bi). In the presence of 10 nmol l)1
SQ29548, the PPARc agonist 15d-PGJ2 enhanced inhibition of
platelet aggregation, suggesting that the effects of PPARc
agonists on collagen-stimulated aggregation, may not be
because of attenutation of TxA2 signaling alone (Fig. 2Bii–iii).
15d-PGJ2 and rosiglitazone signal through PPARc on platelets
To establish whether the effects of PPARc ligands on platelets
are mediated by the receptor (PPARc), similar aggregation
assays were carried out in the presence of the PPARc
antagonist GW9662. Washed human platelets were treated
for 5 min with PPARc antagonist GW9662 alone or followed
incubation for 15 min with PPARc ligands 15d-PGJ2 or
rosiglitazone prior to stimulation for 90 s with collagen
(1 lg mL)1). The PPARc antagonist GW9662 alone (1,
3 lmol L)1) did not modulate the levels of collagen-stimulated
aggregation (Fig. 3A). GW9662 (1 lmol L)1) did, however,
cause a signiﬁcant suppression of the inhibition of collagen-
stimulated platelet aggregation by 15d-PGJ2 and rosiglitazone
(3 lmol L)1) (Fig 3B). These data indicate that the effects of
15d-PGJ2 and rosiglitazone are mediated, at least in part,
through binding to PPARc in platelets.
Rosiglitazone and 15d-PGJ2 inhibit thrombus formation under
arterial flow conditions
The effect of 15d-PGJ2 and rosiglitazone on thrombus
formation in whole blood was examined under arterial ﬂow
conditions in vitro. Whole blood was perfused through
microcapillary tubes coated internally with collagen at a shear
(laminar ﬂow) rate of 1000 s)1 in the presence of rosiglitazone
or 15d-PGJ2 (0.1, 1 and 20 lmol L
)1) or vehicle [DMSO 0.1%
(v/v)]. Thrombus size was calculated from the mean thrombus
volume of ﬁve randomly selected ﬁelds of view. Figure 4A
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(i–iii) shows composite images from Z series captured and
analyzed by confocal microscopy in the presence of vehicle
control and rosiglitazone. Both PPARc ligands, rosiglitazone
and 15d-PGJ2 inhibited the thrombus formation signiﬁcantly
in a concentration-dependent manner, where 1 lmol L)1
rosiglitazone or 15d-PGJ2 were able to inhibit thrombus
formation by 50.4 ± 14.7 % and 66.6 ± 2.7 % compared
with the vehicle control (Fig. 4B). To measure thrombus
formation along the whole capillary, lysis buffer was passed
through each capillary and protein concentration measured as
an indicator of thrombus size. This approach is important
because, as a result of the ﬁbrilar nature of the collagen used,
coating of microslides may not be completely uniform. As this
may inﬂuence data collected from selected ﬁelds, analysis of
platelet recruitment along the entire capillary is quantitatively
more reliable. Consistent with the thrombus volume data,
PPARc ligands resulted in reduced protein concentration
compared with control (Fig. 4C), and no signiﬁcant differences
were noted between rosiglitazone and 15d-PGJ2 treatments.
The inclusion of the PPARc antagonist GW9662 (3 lmol L
)1)
was able to reverse the inhibitory effect of the PPARc ligand
15d-PGJ2 (3 lmol L
)1) on thrombus formation (Fig. 4D).
It is possible that PPARc agonists may reduce thrombus
stability, which may result in greater levels of embolization. To
explore this, thrombi were formed under arterial ﬂow condi-
tions, and subsequently perfused, again at arterial shear rate,
with buffer containing rosiglitazone (1, 20 lmol L)1) or solvent
control. Thrombus volume was subsequently measured by
confocal microscopy. After perfusion, a concentration of
1 lmol L)1 rosiglitazone caused no effect on thrombus stabil-
ity, although an approximate reduction of 10% in thrombus
volume was observed at 20 lmol L)1 (Fig. 4E).
PPARc ligands inhibit P-selectin exposure and
collagen-stimulated mobilization of calcium
Whole citrated blood was pre-incubated with increasing
concentrations of the PPARc ligand rosiglitazone (1, 3, 10
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Fig. 1. Stimulation of peroxisome proliferator-activated receptor-c (PPARc) results in diminished platelet aggregation. Washed human platelets were
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and 20 lmol L)1) or vehicle [DMSO 0.1% (v/v)] for 3 min and
then stimulated with GPVI-selective ligand CRP (1 lg mL)1)
for 3 min and a-granule secretion was assessed by surface
exposure of P-selectin by ﬂow cytometry (Fig. 5A). Rosiglit-
azone was found to inhibit P-selectin exposure. Stimulation of
the collagen receptor GPVI leads to rapid intracellular
mobilization of calcium [33,35]. We therefore examined the
ability of PPARc ligands tomodulate intracellularmobilization
of calcium, on stimulation with collagen. Experiments were
performed in the presence of 2 mmol l)1 EGTA to prevent
extracellular calcium inﬂux. Fura-2AM-loaded washed plate-
lets were pre-incubated with increasing concentrations of
rosiglitazone (1, 3, 10 and 20 lmol L)1) or vehicle [DMSO
0.1% (v/v)] for 3 min and then stimulated with collagen
(1 lg mL)1). Rosiglitazone caused inhibition of collagen-
stimulated peak calcium concentrations (Fig. 5B). It is inter-
esting to note that some aspects of platelet function show
different levels of inhibition by a given concentration of PPARc
agonist, which may also point towards mechanisms of action.
PPARc ligands inhibit the tyrosine phosphorylation of
components of the GPVI signaling pathway
To begin to explore the mechanism through which PPARc
ligands inhibit collagen receptor-mediated signaling the effect
of these ligands on the tyrosine phosphorylation of a number of
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receptor-proximal components of the GPVI signaling pathway
was examined. Platelets were stimulated in the presence of
EGTA (1 mmol l)1), apyrase (2 U mL)1) and indomethacin
(10 lmol L)1) to prevent aggregation and ensure the study of
primary signaling events. In collagen signaling studies, where
non-aggregation conditions are necessary, collagen concentra-
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)1) was incubated for 5 min prior
addition of PPARc ligand or vehicle and thrombus volume analyzed (D). To assess the impact of exposure of pre-formed thrombi to PPARc agonist,
formed thrombi were perfused at an arterial shear rate with rosiglitazone or solvent control for 5 min, and thrombus volume measured by confocal
microscopy (E). Numerical data represent percentage of inhibition compared with control, mean ± SEM (n = 4) t-test * P £ 0.05, ** P £ 0.01 and
*** P £ 0.001.
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tions required to observe signaling were increased (25 lg
mL)1) in order to observe tyrosine phosphorylation of
components of the GPVI pathway, consistent with previous
reports [32,33]. PPARc ligand concentrations used were
therefore also increased.
The effect of rosiglitazone on collagen-stimulated tyrosine
phosphorylation of Syk, LAT and PLCc2 was investigated.
Treatment of platelets with rosiglitazone was without amarked
effect on the levels of collagen-stimulated tyrosine phosphor-
ylation of Syk (Fig. 6A), although a trend for low-level
inhibition that did not reach signiﬁcance was observed. In
contrast, rosiglitazone was found to cause a marked and
concentration-dependent reduction in the levels of tyrosine
phosphorylation of LAT (Fig. 6B) and PLCc2 (Fig. 6C). The
treatment of platelets with the PPARc ligand rosiglitazone was
found to result in inhibition of PI3-K activity as the levels of
serine phosphorylation of a downstream marker of PI3-K
signaling, Akt/PKBa, were reduced (Fig. 6D).
PPARc interacts with Syk and LAT upon stimulation of the
GPVI pathway
As in the presence of PPARc agonists tyrosine phosphorylation
of Syk remained unaffected, while downstream LAT phos-
phorylation was inhibited signiﬁcantly, it was hypothesized
that PPARcmay interact with Syk and/or LAT. In order to test
this, Syk and LAT were immuno-precipitated from platelets
treated with rosiglitazone (10–100 lmol L)1) for 15 min prior
to their stimulation with collagen (25 lg mL)1) and immuno-
blot analyses were conducted to detect PPARc. PPARc was
found to interact with Syk and LAT when platelets were
stimulated with collagen in the absence of PPARc ligands
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Fig. 6. The peroxisome proliferator-activated receptor-c (PPARc) ligand rosiglitazonemodulates glycoprotein VI (GPVI) signaling.Washed platelets were
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(Fig. 7A–B). In the presence of the PPARc ligand rosiglitazone,
this interaction with both Syk and LAT was inhibited. The
inhibitory effect on the PPARc–Syk interaction was prevented
by the addition of the PPARc antagonist GW9662 (3 lmol
L)1) (Fig. 7C), indicating that this effect is PPARc activation
dependent. GW9662 also prevented rosiglitazone-dependent
inhibition of PPARc–LAT interactions (data not shown).
The inhibitory effect of PPARc ligands on platelet function is
not PECAM-1 dependent
Platelet endothelial cell adhesion molecule-1 (PECAM-1), has
been reported to negatively regulate platelet function and
thrombus formation [28,30,36]. Type 2 diabetes mellitus has
been shown to be associated with the cleavage of platelet
PECAM-1. These changes were reverted in patients treated
with rosiglitazone, leading Randriamboavonjy et al. [37] to
suggest that rosiglitazone may contribute to a decrease in the
development of vascular diseases associated with type 2
diabetes mellitus through actions on PECAM-1. In order to
establish if the inhibitory effect of collagen-stimulated platelet
function by acute exposure to PPARc ligands in vitro was
dependent on PECAM-1, the effect of rosiglitazone on platelet
aggregation was examined using washed platelets from
PECAM-1-deﬁcient mice.
Consistent with previous reports [30,36], platelets derived
from PECAM-1-deﬁcient mice exhibit a mildly exaggerated
GPVI-mediated aggregation response to collagen when com-
pared with wild-type mouse platelets (controls Fig. 8A,B:
reduced lag phase and faster initial kinetics). Collagen-stimu-
lated platelet aggregation in wild-type and PECAM-1-deﬁcient
platelets was inhibited in the presence of PPARc ligand
rosiglitazone, when compared with the vehicle control
(Fig. 8A–C). This indicates that the acute (i.e. non-genomic)
inhibitory effects of rosiglitazone on platelet function are not
dependent on the presence or function of PECAM-1.
Discussion
While platelets are anucleate cells, recent reports have demon-
strated that nuclear receptors such as the glucocorticoid
receptor [15], RXR [17] and PPAR isoformsc [13] and b/d
[14] are expressed in these cells. Indeed, these studies have
demonstrated the ability of ligands for intracellular receptors to
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Fig. 7. Peroxisome proliferator-activated receptor-c (PPARc) interacts with Syk and LAT upon platelet stimulation with collagen. Washed platelets were
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regulate platelet function in a non-genomic fashion [13–19].
PPARc can be activated by a number of ligands, including
lipids and eicosanoids, such as 5,8,11,14-eicosatetraynoic acid
and the prostanoids PGA1, PGA2, PGD2 and 15d-PGJ2,
docosahexaenoic acid, linoleic acid and the synthetic anti-
diabetic glitazones (e.g. rosiglitazone) [10,11].
PPARc ligands have been reported to inhibit platelet
aggregation in response to ADP that is accompanied by a
reduction in markers of platelet activation such as P-selectin
exposure, TXA2 synthesis and sCD40L release [13]. Recently,
we demonstrated that RXR ligands inhibit platelet activation
stimulated by ADP or the TXA2 mimetic U46619 and have
proposed this to be mediated through suppression of Gq
signaling, resulting in inhibition of mobilization of calcium
from intracellular stores [17]. Although this has yet to be
explored, the ability of PPARc to interact with RXR may
suggest some overlapping modes of action.
In this study, we have demonstrated that PPARc ligands
inhibit collagen-stimulated platelet aggregation, a-granule
secretion and calcium mobilization. In the presence of the
PPARc antagonist GW9662, inhibition of aggregation was
reversed, suggesting that this affect is at least in part, modulated
by PPARc in platelets. Failure to completely reverse inhibition
indicates potential additional, and as yet uncharacterized,
PPARc-independent modes of action of these ligands.
Increased concentrations of rosiglitazone or 15d-PGJ2 were
associated with more accentuated levels of shape change upon
stimulation with collagen. This is likely to reﬂect lower levels of
aggregation in this optical assay, as PPARc agonists alone do
not stimulate shape change. We cannot, however, rule out the
possibility that PPARc normally serves to inhibit shape change.
As PPARc agonists were found to inhibit collagen-stimu-
lated calcium mobilization, a range of signaling proteins
upstream of calcium in the GPVI collagen activation pathway
were examined. Rosiglitazone did not cause marked inhibition
of collagen-stimulated tyrosine phosphorylation of the kinase
Syk, suggesting that the activity of upstreamSrc-family kinases,
such Fyn and Lyn, is not modulated by PPARc ligands. This
ligand was, however, found to reduce the levels of tyrosine
phosphorylation of the transmembrane adapter protein LAT
and thereby PLCc2, which is consistent with the inhibition of
calcium regulation and a-granule secretion.
The tyrosine phosphorylation of LAT results in the recruit-
ment and activation of PI3-K, leading to the generation of
3¢-phosphorylated inositol phospholipid second messengers.
Rosiglitazone treatment resulted in diminished collagen-stimu-
lated phosphorylation of Akt/PKBa, suggesting that the inhib-
itory effect of the PPARc stimulation also results in suppression
of PI3-K signaling. In the present study, interactions of PPARc
with Syk and LAT highlight a potential novel GPVI-dependent
mechanismforPPARcactiononplateletactivation.PPARc inits
inactivated state interactswithSykandLAT(andpossiblyother
components of the LAT signalosome). These interactions
correlate with phosphorylation of Syk and LAT leading to the
activation of proteins downstream within the GPVI pathway.
Upon ligation of PPARc, interactions with Syk and LAT were
prevented, which coincided with diminished signaling down-
streamresultinginareductioninplateletactivation.Theaddition
of the antagonist GW9662 was able to prevent the inhibitory
effectofPPARc ligandsoninteractionsbetweenPPARcwithSyk
and LAT. Taken together, this suggests that the inhibitory
actions of PPARc ligands may be mediated within the GPVI
signaling pathway at the level of LAT or the LAT signalosome
andthatinhibitionofplateletsbyPPARc ligandsisnotbecauseof
toxic effects. Further work is required to establish whether
PPARc is recruited toa signalingprotein complexwithbothSyk
and LAT, or whether interaction with Syk and LAT occurs
independently. Furthermore, whether PPARc interactions con-
tribute to positive signaling through theGPVIpathway remains
to be established.
It has been suggested that PPARc ligands reduce the develop-
ment of atherosclerosis and myocardial ischemia–reperfusion
injury through inhibition of platelet activation and intra-arterial
thrombus formation in animal models [38]. In support of this
notion, we have observed that PPARc ligands rosiglitazone and
15d-PGJ2, inhibit thrombus formation in human whole blood
on immobilized collagen under arterial ﬂow conditions.
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Furthermore, perfusion with a low concentration of rosiglitaz-
one, which is likely achievable in plasma of patients taking
rosiglitazone (1 lmol L)1) [39], caused no effect on thrombus
stability. Together this suggests that PPARc ligands may offer
beneﬁcial clinical actions through inhibition of thrombus
formation without embolization effects. Future studies using in
vivomodelsof thrombosiswillberequiredtoexplore this further.
Treatment with TZDs such as rosiglitazone has been
reported to reduce the activity of circulating platelets in
patients with coronary artery disease [40] and type 2 diabetes
mellitus [41]. More recently, treatment of type 2 diabetes with
rosiglitazone has been reported to cause decreases in l-calpain
activity, the restoration of platelet PECAM-1 levels and
diminished platelet responsiveness to thrombin [37]. As
PECAM-1 and PPARc ligands are able to inhibit the function
of platelets, and they possess similar abilities to modulate
calcium mobilization in these cells, we sought to determine
whether the acute, non-genomic actions of rosiglitazone may
be dependent on PECAM-1 expression. Examination of
PECAM-1-deﬁcient mouse platelets revealed, however, that
the inhibitory effect of collagen-stimulated platelet aggregation
by PPARc ligands is unaffected by the presence or absence of
PECAM-1. The possibility still exists, however, that PPARc
and PECAM-1 share similarities in their modes of modulation
of GPVI-stimulated signaling in platelets.
Clinical trials have demonstrated that the treatment of
diabetic patients with TZDs exerts a cardioprotective effect as
evidenced by a reduction in the risk of myocardial infarction in
diabetic patients [24–26,40]. However, there are conﬂicting
reports demonstrating that administration of PPARc agonists
may be associated with an increased incidence of congestive
heart failure, myocardial infarct and death [42–44]. These latter
studies were limited by a lack of access to original source data,
and were insufﬁciently statistically powered. Better character-
ization of such patients is therefore needed to determine the
effect of TZDs on overall cardiovascular outcome.
Our ﬁndings indicate that PPARc ligands inhibit collagen-
stimulated platelet function through modulation of signaling
downstream of the collagen receptor GPVI.
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